Drug Profile
HL 02
Alternative Names: HL02Latest Information Update: 28 Sep 2021
Price :
$50
*
At a glance
- Originator Hualan Genetic Engineering
- Class Antineoplastics
- Mechanism of Action ERBB 2 receptor modulators; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Breast cancer
Most Recent Events
- 28 Sep 2021 No recent reports of development identified for preclinical development in Breast-cancer in China (Injection)
- 16 Aug 2017 Preclinical trials in Breast cancer in China, before August 2017 (ChiCTR-RIC17012372)
- 16 Aug 2017 First Hospital of Jilin University and Hualan Genetic Engineering plans a phase I trial for Breast cancer (In volunteers) in China in September 2017 (ChiCTR-RIC17012372)